S&P 500   4,596.62 (+0.66%)
DOW   35,869.51 (+0.36%)
QQQ   381.33 (+0.90%)
AAPL   149.53 (+0.60%)
MSFT   308.78 (+0.21%)
FB   322.50 (-1.88%)
GOOGL   2,778.99 (+1.09%)
TSLA   1,066.36 (+4.05%)
AMZN   3,400.66 (+2.42%)
NVDA   245.91 (+6.15%)
BABA   172.41 (-2.13%)
NIO   42.12 (+2.06%)
CGC   13.36 (-1.55%)
GE   109.50 (+3.99%)
AMD   125.18 (+2.30%)
MU   69.36 (+0.87%)
T   25.66 (+0.08%)
F   16.02 (+0.13%)
ACB   7.08 (-1.39%)
DIS   172.14 (+0.08%)
PFE   43.12 (-0.07%)
BA   214.11 (+0.58%)
AMC   36.55 (-0.76%)
S&P 500   4,596.62 (+0.66%)
DOW   35,869.51 (+0.36%)
QQQ   381.33 (+0.90%)
AAPL   149.53 (+0.60%)
MSFT   308.78 (+0.21%)
FB   322.50 (-1.88%)
GOOGL   2,778.99 (+1.09%)
TSLA   1,066.36 (+4.05%)
AMZN   3,400.66 (+2.42%)
NVDA   245.91 (+6.15%)
BABA   172.41 (-2.13%)
NIO   42.12 (+2.06%)
CGC   13.36 (-1.55%)
GE   109.50 (+3.99%)
AMD   125.18 (+2.30%)
MU   69.36 (+0.87%)
T   25.66 (+0.08%)
F   16.02 (+0.13%)
ACB   7.08 (-1.39%)
DIS   172.14 (+0.08%)
PFE   43.12 (-0.07%)
BA   214.11 (+0.58%)
AMC   36.55 (-0.76%)
S&P 500   4,596.62 (+0.66%)
DOW   35,869.51 (+0.36%)
QQQ   381.33 (+0.90%)
AAPL   149.53 (+0.60%)
MSFT   308.78 (+0.21%)
FB   322.50 (-1.88%)
GOOGL   2,778.99 (+1.09%)
TSLA   1,066.36 (+4.05%)
AMZN   3,400.66 (+2.42%)
NVDA   245.91 (+6.15%)
BABA   172.41 (-2.13%)
NIO   42.12 (+2.06%)
CGC   13.36 (-1.55%)
GE   109.50 (+3.99%)
AMD   125.18 (+2.30%)
MU   69.36 (+0.87%)
T   25.66 (+0.08%)
F   16.02 (+0.13%)
ACB   7.08 (-1.39%)
DIS   172.14 (+0.08%)
PFE   43.12 (-0.07%)
BA   214.11 (+0.58%)
AMC   36.55 (-0.76%)
S&P 500   4,596.62 (+0.66%)
DOW   35,869.51 (+0.36%)
QQQ   381.33 (+0.90%)
AAPL   149.53 (+0.60%)
MSFT   308.78 (+0.21%)
FB   322.50 (-1.88%)
GOOGL   2,778.99 (+1.09%)
TSLA   1,066.36 (+4.05%)
AMZN   3,400.66 (+2.42%)
NVDA   245.91 (+6.15%)
BABA   172.41 (-2.13%)
NIO   42.12 (+2.06%)
CGC   13.36 (-1.55%)
GE   109.50 (+3.99%)
AMD   125.18 (+2.30%)
MU   69.36 (+0.87%)
T   25.66 (+0.08%)
F   16.02 (+0.13%)
ACB   7.08 (-1.39%)
DIS   172.14 (+0.08%)
PFE   43.12 (-0.07%)
BA   214.11 (+0.58%)
AMC   36.55 (-0.76%)
CVE:EBN

Epicore BioNetworks Stock Forecast, Price & News

C$1.29
-0.01 (-0.77 %)
(As of 12/14/2017)
Add
Compare
Today's Range
C$1.29
C$1.29
50-Day Range
C$1.29
C$1.29
52-Week Range
C$0.54
C$1.32
Volume54,778 shs
Average Volume29,654 shs
Market CapitalizationC$34.03 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive EBN News and Ratings via Email

Sign-up to receive the latest news and ratings for Epicore BioNetworks and its competitors with MarketBeat's FREE daily newsletter.


About Epicore BioNetworks

Epicore BioNetworks Inc. (Epicore) develops, manufactures and markets specialty biotechnology, biochemical and nutrition products. Epicore specialty biochemical products are mixtures of specialty organic, inorganic and biochemical ingredients that facilitate microbe and plant growth. Some Epicore products (such as its EPIZYM-AGP COMPLETE) stimulate algae growth, an important property in shrimp and bivalve hatcheries that grow algae as animal food. Some of its products (such as EPIZYM-BGM) support microbe growth for customers who grow-up an Epicore microbial ecosystem at their location. Some Epicore biochemical products stimulate plant growth to increase plant yield and environmental stress resistance. The third Epicore product group is specialty animal feeds. These products are an extension of its microbial growth media expertise and are primarily used in aquaculture. Its EPIFEED -LHF and EPILITE liquid shrimp larval feeds are tools to help hatchery managers raise postlarval shrimp.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Industry
Electronic Computer Manufacturing
Sub-Industry
N/A
CIK
N/A
Employees
147,000
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
C$34.03 million
Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.93 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Epicore BioNetworks (CVE:EBN) Frequently Asked Questions

What stocks does MarketBeat like better than Epicore BioNetworks?

Wall Street analysts have given Epicore BioNetworks a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Epicore BioNetworks wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Epicore BioNetworks' key executives?

Epicore BioNetworks' management team includes the following people:
  • William P. Long, President, Chief Executive Officer, Chief Operating Officer, Director
  • Russell Rosenzweig, Chief Financial Officer, Company Secretary
  • Robert Stephen Poulton, Non-Executive Chairman of the Board
  • Donald R. Siemens, Director
  • Stefan Zaphiriou Zarifi, Director
  • Alan C. Savage, Independent Director

Who are some of Epicore BioNetworks' key competitors?

What other stocks do shareholders of Epicore BioNetworks own?

What is Epicore BioNetworks' stock symbol?

Epicore BioNetworks trades on the Canadian Venture Exchange (CVE) under the ticker symbol "EBN."

How do I buy shares of Epicore BioNetworks?

Shares of EBN and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Epicore BioNetworks' stock price today?

One share of EBN stock can currently be purchased for approximately C$1.29.

How much money does Epicore BioNetworks make?

Epicore BioNetworks has a market capitalization of C$34.03 million.

How many employees does Epicore BioNetworks have?

Epicore BioNetworks employs 147,000 workers across the globe.

What is Epicore BioNetworks' official website?

The official website for Epicore BioNetworks is epicorebionetworks.com.

Where are Epicore BioNetworks' headquarters?

Epicore BioNetworks is headquartered at 4 Lina Ln, EASTAMPTON, NJ 08060-5414, United States.

How can I contact Epicore BioNetworks?

Epicore BioNetworks' mailing address is 4 Lina Ln, EASTAMPTON, NJ 08060-5414, United States. The company can be reached via phone at +1-609-2679118.


This page was last updated on 10/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.